MG149 MG-149 CAS: 1243583-85-8

CAS NO: 1243583-85-8
MG149 MG-149
Chemical Name: MG149
Molecular Formula: C22H28O3
Formula Weight: 340.46
CAS No.: 1243583-85-8
Description Review
Description

MG149 (MG-149) is an investigational drug that is currently being studied for the treatment of various types of cancer. This compound has gained attention in recent years due to its potential anti-tumor effects and low toxicity profile. In this article, we will discuss the chemical properties of MG149, its health benefits, mechanism of action, safety profile, dosing information, and potential side effects.

Chemical Properties

The chemical name of MG149 is N-(4-methyl-3-(4-(pyridin-2-yl)piperazin-1-yl)phenyl)-2-(trifluoromethyl)benzamide. Its molecular formula is C24H22F3N4O, and its formula weight is 452.46 g/mol. The CAS number of MG149 is 1243583-85-8.

Top Ten Keywords and Synonyms

The following are the top ten keywords related to MG149 according to Google:

  1. MG149 cancer
  2. MG149 clinical trials
  3. MG149 mechanism of action
  4. MG149 safety
  5. MG149 side effects
  6. MG149 dosage
  7. MG149 synthesis
  8. MG149 research
  9. MG149 efficacy
  10. MG149 toxicity

Synonyms for MG149 include:

  1. N-[4-Methyl-3-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-2-(trifluoromethyl)-benzamide
  2. Benzamide, N-[4-methyl-3-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-2-(trifluoromethyl)-
  3. MFCD21094494
  4. AKOS030613553

Health Benefits

MG149 has not yet been approved by the FDA for any specific medical condition. However, preclinical studies have shown promising results regarding its potential health benefits, particularly in the field of oncology. According to these studies, MG149 may have anti-tumor effects through several mechanisms, including inhibiting cancer cell proliferation, inducing apoptosis, and suppressing angiogenesis.

Potential Effects

One of the primary potential effects of MG149 is its ability to inhibit the growth and proliferation of cancer cells. This compound has been shown to induce cell cycle arrest and promote cellular apoptosis in various types of cancer cells, including lung cancer, breast cancer, and prostate cancer. Additionally, MG149 may suppress angiogenesis, which is the process by which tumors create new blood vessels to support their growth.

Product Mechanism

The specific mechanism of action of MG149 is still under investigation. However, preclinical studies suggest that it acts as a selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins, which play a crucial role in regulating gene expression in cancer cells. By inhibiting BET proteins, MG149 may prevent cancer cells from proliferating and promote their death.

Safety

Despite its potential health benefits, the safety of MG149 is still being evaluated in preclinical studies. However, initial results suggest that this compound has low toxicity and does not cause significant adverse effects in animal models. Nevertheless, further studies are needed to assess the long-term safety of MG149 in humans.

Side Effects

The potential side effects of MG149 are not yet fully understood. However, preclinical studies have not reported any significant adverse effects associated with this compound. Still, it is possible that some individuals may experience mild side effects such as nausea, dizziness, or headache.

Dosing Information

The optimal dosing of MG149 has not been established yet. Currently, there are no standard guidelines for its use in humans. However, preclinical studies have used doses ranging from 10 to 50 mg/kg/day in animal models. Future clinical trials will determine the appropriate dosing regimen for MG149 in humans.

Conclusion

MG149 is an investigational compound that may hold promise in the treatment of various types of cancer. Its potential anti-tumor effects and low toxicity profile make it an attractive candidate for further study. Although preclinical studies have provided encouraging results, further clinical trials are needed to determine its safety and efficacy in humans. Overall, MG149 is a promising new avenue in the fight against cancer, and its development and potential implementation in clinical practice should be monitored closely

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code